{"id":"NCT03583372","sponsor":"Urovant Sciences GmbH","briefTitle":"An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).","officialTitle":"An International Phase 3, Randomized, Double-Blind, Active (Tolterodine)-Controlled Multicenter Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-14","primaryCompletion":"2019-06-13","completion":"2019-07-25","firstPosted":"2018-07-11","resultsPosted":"2021-02-03","lastUpdate":"2021-03-18"},"enrollment":506,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Overactive Bladder"],"interventions":[{"type":"DRUG","name":"Vibegron","otherNames":["RVT-901, MK-4618, KRP114V"]},{"type":"DRUG","name":"placebos","otherNames":[]},{"type":"DRUG","name":"Tolterodine Tartrate ER","otherNames":["Mariosea XL"]}],"arms":[{"label":"Vibegron + Placebo to match Tolterodine","type":"EXPERIMENTAL"},{"label":"Tolterodine + Placebo to match vibegron","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in participants with OAB for up to 52 weeks.","primaryOutcome":{"measure":"Number of Participants With the Indicated Type of Treatment-emergent Adverse Event","timeFrame":"up to 56 weeks","effectByArm":[{"arm":"Overall Vibegron 75 mg","deltaMin":171,"sd":null},{"arm":"Overall Tolterodine ER 4 mg","deltaMin":126,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":107,"countries":["United States"]},"refs":{"pmids":["33356445"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":273},"commonTop":["Hypertension","Urinary tract infection","Nasopharyngitis","Headache","Dry mouth"]}}